Mohamad Ali Rida

Mohamad Ali Rida

Auto-generated profile, based on publicly available information

Mohamad Ali Rida

Department of Dermatology, Faculty of medicine and medical sciences, University of Balamand , Balamand

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2023 in Arthritis Care & Research
Verified
Journal Article
Open access
MRMohamad‐Ali Rida
Mohamad‐Ali Rida
KLKer‐Ai Lee
Ker‐Ai Lee
VCVinod Chandran
Vinod Chandran
RCRichard J. Cook
Richard J. Cook
DGDafna D. Gladman
Dafna D. Gladman
Objective: To analyze the trends in biologics use at a specialized center over a period of 20 years.Methods: We performed a retrospective analysis of 571 patients diagnosed with psoriatic arthritis enrolled in the Toronto cohort who initiated biologic therapy between January 1, 2000, and July 7, 2020. The probability of drug persistence over time was estimated nonparametrically. The time to discontinuation of first and second treatment was analyzed using Cox regression models, whereas a semiparametric failure time model with a gamma frailty was used to analyze the discontinuation of treatment over successive administrations of biologic therapy.Results: The highest 3‐year persistence probability was observed with certolizumab when used as first biologic treatment, while interleukin‐17 inhibitors had the lowest probability. However, when used as second medication, certolizumab had the lowest drug survival even when accounting for selection bias. Depression and/or anxiety were associated with a higher rate of drug discontinuation due to all causes (relative risk [RR] 1.68, P = 0.01), while having higher education was associated with lower rates (RR 0.65, P = 0.03). In the analysis accommodating multiple courses of biologics, a higher tender joint count was associated with a higher rate of discontinuation due to all causes (RR 1.02, P = 0.01). Older age at the start of first treatment was associated with a higher rate of discontinuation due to side effects (RR 1.03, P = 0.01), while obesity had a protective role (RR 0.56, P = 0.05).Conclusion: Persistence in taking biologics depends on whether the biologic was used as first or second treatment. Depression and anxiety, higher tender joint count, and older age lead to drug discontinuation.

10 May 2023 in Rheumatology
Verified
Journal Article
Open access
MKMarcel Katrib
Marcel Katrib
RHRafi Haddad
Rafi Haddad
ZHZahi Hamdan
Zahi Hamdan
MRMohamad Ali Rida
Mohamad Ali Rida
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease. The sex hormones estrogen and testosterone may have an influence on the production of antibodies. In addition, the gut microbiota also shows an effect on the onset and progression of SLE. Hence, the molecular interplay between sex hormones in terms of gender difference, gut microbiota and SLE is being clarified day after day. The aim of this review is to investigate the dynamic relationship of the gut microbiota with sex hormones in systemic lupus erythematosus taking into account the bacterial strains shown to be affected, effects of antibiotics and other factors that affect the gut microbiome, which itself strong-ly affects the pathogenesis of SLE.

18 August 2024 in World Journal of Orthopedics
Verified
Journal Article
Open access
SSSomar Soufan
Somar Soufan
JKJoenne Al Khoury
Joenne Al Khoury
ZHZahi Hamdan
Zahi Hamdan
MRMohamad Ali Rida
Mohamad Ali Rida
Osteoarthritis (OA) poses a substantial burden on patients, leading to pain, functional decline, and reduced quality of life. While conventional treatments focus on symptom management, disease-modifying interventions are yet to be established. This review explores the efficacy of intra-articular interventions, particularly hyaluronic acid (HA), mesenchymal stem cells (MSCs), and platelet-rich plasma (PRP), in the context of OA management. HA injections, with diverse formulations like Hylan G-F20, sodium hyaluronate, and hyaluronan, present varying outcomes, necessitating a nuanced understanding of their effectiveness and timing. MSC therapy, derived from adipose tissue, umbilical cord, or bone marrow, shows promising results in clinical improvement, with adipose-derived MSCs demonstrating efficacy in maintaining benefits over 6 mo. Conversely, bone-marrow-derived MSCs show limited effectiveness, highlighting the need for source-specific considerations. PRP has emerged as a superior option for long-term pain reduction and quality of life improvement, with leukocyte-poor formulations and a critical platelet count of 10 billion demonstrating optimal results. This comprehensive analysis underscores the potential of intra-articular interventions in OA management, emphasizing the need for personalized and evidence-based approaches to enhance treatment efficacy and patient outcomes.


20 September 2025 in World Journal of Experimental Medicine
Verified
Journal Article
Open access
ECElie Chamchoum
Elie Chamchoum
NKNadia Katrib
Nadia Katrib
NNNicolas Nassif
Nicolas Nassif
YRYara Ratel
Yara Ratel
MRMohamad Ali Rida
Mohamad Ali Rida
Glucagon-like peptide-1 (GLP-1) and its receptor agonists (GLP-1RAs) are well-established therapies for metabolic conditions such as type 2 diabetes and obesity due to their ability to enhance insulin secretion, promote weight loss, and regulate blood glucose levels. Emerging evidence, however, indicates that GLP-1RAs may also have therapeutic potential in inflammatory and autoimmune conditions. This review explores the evolving role of GLP-1RAs in managing rheumatic diseases, including osteoarthritis, rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Studies suggest that GLP-1RAs reduce inflammation by modulating immune cell activity, increasing anti-inflammatory cytokine production, shifting macrophage polarization toward an anti-inflammatory phenotype, and enhancing regulatory T-cell function to maintain immune homeostasis. These immunomodulatory effects point toward a promising adjunctive strategy in current clinical practice for patients with rheumatic diseases, particularly those with metabolic comorbidities. Further clinical trials are warranted to validate these findings, clarify underlying mechanisms, and assess long-term safety, ultimately paving the way for novel treatment approaches in rheumatology.

1 June 2020 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
MRMohamad Ali Rida
Mohamad Ali Rida
DGDafna D. Gladman
Dafna D. Gladman
Psoriatic arthritis (PsA) is one of the major extra skin manifestations of psoriasis and will develop in 20–30% of patients with psoriasis1. Alternative medicines, mainly herbal products, have been commonly used by patients for the treatment of psoriasis and there have been some studies into their efficacy, but most cases of PsA still require systemic therapy2.